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S316 Poster Session IIof regimens. Even with therapeutic drug monitoring of Bu, by the
time results come back, patients may have had 1 or 2 days of high
or low exposure. The required dose change to target a desired cumu-
lative AUC may exceed the clinicians’ willingness to make such
a change. We report here our use of a novel dosing schedule which
always avoids high exposure and is compatible with samples being
sent across long distances for analysis.
Methods: 96 patients from 6 institutions were given Bu over 5 days.
Regimens included BuCy(n5 36), BuFlu(n5 24). Four blood sam-
ples were collected after infusion of a half dose on day 1 and trans-
ported to CHW. On day 2 the second half dose was given whilst
Bu measurement and pharmacokinetic analysis was completed. A
full dose AUC was predicted from the half dose results. On days 3
to 5 patients were administered the remaining Bu doses, modified
where necessary based on the day 1 AUC. In 71 patients, repeat
AUC analysis after a full dose allowed comparison of predicted
with actual AUC.
Results:The day 1 analysis predicted a full dose AUC range between
3148 and 12666mM.min. Thirty four patients would have had an
AUC . 6000mM.min. For days 3 to 5, 34 had doses reduced and
10 had doses increased to target a desired AUC. After dose adjust-
ments, the repeat AUCwas within610% predicted in 38 and within
615% in 51. Two of 36 adults had a final AUC value. 6000mM.min
(but only 6097 and 6187).
Conclusions:There was a wide variability in Bu exposure following
the first dose: 35% of the patients were predicted to be exposed to
levels above the recommended level of 6000mM.min. With dose ad-
justment, targeted dose exposure was within 615% of predicted
values in 72% of patients and no adult was exposed to an AUC sig-
nificantly . 6000mM.min. This novel dosing schedule allows real-
time pharmacokinetic dose adjustment in multiple centres across
Australia and avoids the problem of having to catch up, or back off
on day 3 and 4 dosing. It is simple and lends itself to centres that
are remote from the lab testing the Bu levels. The impact of concom-
itant medication on the remaining variability in exposure continues
to be studied.
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PILOT STUDY ON THE MEASUREMENT OF CALCINEURIN PHOSPHATASE
ACTIVITY ON DAY 21 IN ALLOGENEIC STEM CELL RECIPIENTS
Moon, J.H.1, Sohn, S.K.1, Do, Y.R.2, Lee, S.J.1, Kang, B.W.1,
Chae, Y.S.1, Kim, J.G.1 1Kyungpook National University Hospital,
Daegu, Korea; 2Keimyung University Dongsan Medical Cente, Daegu,
Korea
Background: Tacrolimus (TAC) suppress T-cell activation by the
action on calcineurin (CN). CN activity was assessed in the alloge-
neic recipients who were treated with TAC for graft-versus-host dis-
ease (GVHD) prophylaxis to investigate whether CN activity
increased in patients with severe acute GVHD.
Methods: Forty patients who underwent allogeneic stem cell trans-
plantation (SCT) using TAC as GVHD prophylaxis were analyzed
for GVHD. Among them, CN activity was analyzed in the 10 con-
secutive patients. TAC was administered at a dose of 0.03 mg/kg in-
travenously from day-1 to +21. TAC levels and CN activity were
assessed on day-1 before TAC administration and days 0, +3, +7,
+14, and +21. Target TAC concentration (15-20 ng/ml) was main-
tained during the current study.
Results: The cumulative incidence of acute GVHD (74.1% vs.
60.3%, p 5 0.888) and severe chronic GVHD (22.5% vs. 33.3%, p
5 0.539) were not different between groups with high and low
TAC trough levels. CN activity on day-1 was 0.1260.09 nmol and
had decreased from baseline level (0.2960.15 nmol) (p\ 0.001).
There was no correlation between CN activity and TAC concentra-
tions (r2 5 0.024). CN activity was steady-state during post-trans-
plant day+0 to +14 regardless of acute GVHD, CN activity on
day+21 for those with grade 2-4 acute GVHD showed a higher
CN activity (0.1860.04 nmol) compared to those without grade 2-
4 acute GVHD (0.1460.05 nmol, p 5 0.462). The cumulative inci-
dence of acute GVHD (40% vs. 80%, p 5 0.248) and chronic
GVHD (20% vs. 70%, p5 0.464) between low and high CN activity
group were not significantly different.
Conclusion: Although GVHD was higher for the high CN activity
group, this pilot study failed to demonstrate significant difference
due to small sample size. However, the patients manifestingGVHD with high CN activity on post-transplant D+21 may need
to be treated with other kinds of immunosuppressive agent regard-
less of drug level.
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CHARACTERIZATIONOF ORAL INVOLVEMENT IN ACUTE-GRAFT-VERSUS-
HOST DISEASE
Ion, D.I.1, Stevenson, K.E.2,Woo, S.-B.1,3, Antin, J.H.4,5, Soiffer, R.J.4,5,
Treister, N.S.1,3 1Brigham and Women’s Hospital, Boston, MA;
2Dana-Farber Cancer Institute, Boston, MA; 3Harvard School of Dental
Medicine, Boston, MA; 4Dana-Farber Cancer Institute, Boston, MA;
5Harvard Medical School, Boston, MA
Introduction: Acute graft-versus-host-disease (aGVHD) is a major
complication of allogeneic hematopoietic cell transplantation
(HCT). The purpose of this study was to characterize the oral
features associated with aGVHD.
Methods:Patients that underwent allogeneicHCTatDana-Farber/
Brigham and Women’s Cancer Center (Boston, MA) between 1995
and 2010 and developed prominent oral aGVHD were identified.
Data was collected from patientmedical records using a standardized
form and analyzed descriptively.
Results:Eighteen cases were identified, of which 5 (28%) only dem-
onstrated oral features; the remaining 13 had variable involvement of
skin (13/18, 72%), liver (6/18, 33%), and gut (5/18, 28%). Oral mu-
cositis preceded aGVHD in 10 (56%) patients. The median time to
onset of oral aGVHD was 34 days (range 11-159). Intraoral sites af-
fected by non-specific ulcerations included the tongue (16/18, 89%;
dorsum in 7/18), buccal mucosa (16/18, 89%), labial mucosa (13/18,
72%), palate (12/18, 67%; hard palate in 7/18), and floor of mouth
(6/18; 33%); 7 (39%) cases presented with prominent lip ulceration
and crusting. Salivary gland disease features included severe hypo-
function (1/18; 6%) and palatal mucoceles (1/18; 6%). In addition
to systemic therapies, topical preparations of dexamethasone (10/
18; 56%), tacrolimus (7/18; 39%), and morphine (3/18; 17%) were
utilized for ancillary support. Of the 13 (72%) patients that survived
beyond day100, two developed oral cGVHD.
Conclusions: Oral features of aGVHD include extensive non-spe-
cific ulcerations of keratinized and non-keratinized mucosa and are
often observed in the context of concurrent skin, liver and gut in-
volvement. Intensive topical therapies may be helpful in reducing
symptoms and promoting healing. Concurrent salivary gland
involvement appears to be infrequent.
Relevance: Oral medicine specialists can play an important role in
both its diagnosis and management; the HCT team should be aware
that aGVHD can present with oral features that might be responsive
to topical therapies.
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SCREENING FOR HEMOGLOBINOPATHIES IN ALLOGENEIC CORD BLOOD
UNITS USING CAPILLARY ELECTROPHORESIS
Damianitsch, K., Platz, A., Schmidt, A., Ehninger, G. DKMSCord Blood
Bank, Blasewitzer Straße 43, Dresden, Germany
Introduction: Hemoglobinopathies are common hereditary dis-
eases with very different clinical outcomes. Since severe hemoglobin-
opathies like sickle cell anemia or thalassemia major are by
themselves indications for transplantation, these inborn errors are
relevant screening parameters for transplantation centers. In line
with that, the international FACT-Netcord standards for the storage
and release of cord blood units for transplantation (4th edition) state
that screening for homozygous hemoglobinopathies is mandatory
for cord blood banks storing allogeneic transplants.
Material and Methods: We use the Capillarys 2 hemoglobin elec-
trophoresis machine and the Capillarys cord blood procedure by Se-
bia. Analyses are performed on anti-coagulated cord blood before
volume reduction. The red blood cells are sedimented and plasma
is removed completely. Before measuring the samples are hemolysed
automatically.
Results: So far, a total of 717 measurements were performed. In
1.5% of all samples hemoglobin variants were detected, namely six
cases of Hb Barts, three cases of heterozygous Hb S and one case
of a heterozygous hemoglobin variant, most likely HbE. These sam-
ples were then sent to a specialized laboratory for PCR-testing, and
Poster Session II S317the results obtained there correlated with our findings. All samples
containing Hb Barts were confirmed as a+-Thalassemia minima,
which is a clinically not relevant outcome. The hemoglobin variant
detected in the Hb E-zone turned out to be the heterozygous, and
therefore clinically not relevant, Hb F-Campinas.
Discussion:Hemoglobin electrophoresis using the Capillarys 2 sys-
tem by Sebia proved to be an efficientmethod to screen for hemoglo-
binopathies in cord blood. So far, the ratio of detected
hemoglobinopathies is lower than what previously published studies
suggested. It has to be taken into account that this is not an epidemi-
ological study, but instead relies on a restricted group of patients -
namely newborns that donated Cord Blood.451
IMPACT OF DONOR STEM CELLMOBILIZATION REACTIONS ON REDUCED
INTENSITY HAPLOIDENTICAL HCT OUTCOMES IN MINIATURE SWINE
Duran-Struuck, R.1, Crepeau, R.1, Matar, A.1, Pathiraja, V.1,
Horner, B.1, Robson, S.3, Fishman, J.1, Spitzer, T.2, Sachs, D.1,
Huang, C.1 1Massachusetts General Hospital, Boston, MA; 2Massachu-
setts General Hospital, Boston, MA; 3Beth Israel Deaconess Medical
Center, Boston, MA
Toxicities and complications associated with hematopoietic cell
transplantation (HCT) currently limit this potentially curative ther-
apy for malignant and non-malignant blood disorders in the clinic.
Similar to outcomes in patients, miniature swine develop severe
GVHD, infectious complications or hematopioetic failure following
standard clinical myeloablative conditioning and HCT. Miniature
swine recipients pre-treated with a low-dose (100cGy) of total
body irradiation (TBI), partial T-cell depletion using a CD3-immu-
notoxin prior to HCT and a 45 day course of Cyclosporine A
(referred to as ITC non myeloablative conditioning) following
high-dose haploidentical-HCT (5-15X109 PBMCs/kg) exhibit sta-
ble engraftment and multilineage chimerism. We have observed
a wide variability in engraftment outcomes depending on the occur-
rence of adverse reactions (fever, loss of appetite, bloody diarrhea,
shedding of the GI lining and development of disseminated intravas-
cular coagulopathy [DIC]) in the donor (‘‘DIC Donor’’) following
cytokine mobilization at the time of HC donation. ITC recipients
(n 5 12) that received haploidentical HCT from donors that re-
mained healthy (‘‘Healthy Donors’’) during IL-3 and stem cell factor
(SCF) mobilization, engrafted with multilineage chimerism, did not
develop GVHD and did not require any blood product support. In
contrast, ITC recipients (n 5 11) that received a stem cell product
from a DIC Donor mobilized with IL3 and SCF had adverse out-
comes. All recipients (11/11) lost peripheral blood myeloid chime-
rism (i.e. lack of donor stem cell engraftment). Also, all animals
that received an HCT graft from DIC Donors developed moder-
ate-severe thrombocytopenia (\ 100,000 PLT/uL) and 73% (8/
11) developed severe and life threatening thrombocytopenia (un-
der/equal 20,000 PLT/uL) which required blood product support.
One animal developed grade IV acute GVHD on day 30 post
HCT. In contrast only 2/12 (16%) of animals receiving a transplant
from Healthy Donors had thrombocytopenia with levels falling un-
der 100K, none required blood product support and none developed
GVHD. These data suggest that engraftment outcomes and post-
transplant complications are greatly influenced by the health status
of the donor prior to collection of cells by leukapheresis.We are cur-
rently investigating the causes of possible factors responsible for the
poor engraftment outcomes.
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OUTCOME OF 64 APLASTIC ANEMIA CHILDRENWITH ALLOGENIC HEMA-
TOPOIETIC STEM CELL TRANSPLANT IN CHINA: A REPORT FROM
CHINESE PEDIATRIC GROUP OF HSCT
Chen, J.1, Qin, M.Q.2, Fang, J.P.3, Luan, Z.4, Chai, Y.H.5, Sun, X.6,
Zhu, Y.P.7, Tang, Y.M.8 1Shanghai Jiao Tong University, Shanghai,
China; 2Beijing Capital Medical School Beijing Children’s Hospital;
3Sun Yat-sen University Affiliated Sun Yat-sen Hospital; 4PLA Navy
General Hospital; 5Soochow University Affiliated Children’s Hospital;
6Women and Children’s Hospital of Guang Zhou; 7West China SecondUniversity Hospital; 8Children’s Hospital Zhejiang University School of
Medicine
Objective: to analysis the outcome of allogenic hematopoiteic stem
cell transplant (HSCT) for children with aplastic anemia (AA) in
China. To improve the evidence based HSCT indication for pediat-
ric AA.
Method:: retrospectively analysis pediatric AA receivedHSCT from
2002-2009 in Chinese Pediatric Group of HSCT.
Results: 64 patients from 8 hospitals enrolled in this group(16
VSAA, 44 SAA and 4 CAA). The median age was 7.5 years old (1-
16.5y). Because 5 of 11 received second HSCT totally 69 transplan-
tation were performed with 30 matched sibling donor, 24 matched
unrelated donor and another 15 haploidentical family donor. 53%
received CY120mg+ATG+Flu150-200mg+TBI3GY,38% received
CY120mg+ ATG+ Flu150-200mg and only 9% received CY120m-
g+ATG condition regimen. For the sources of hematopoietic stem
cell 45% with PB, 34% with PB+BM,17% with BM and only 4%
with CB. After median follow up 26 months (10-95 months) 11 of
64(15.9%) suffered graft failure (3 with secondary graft failure).ex-
cept 2 lost follow up post transplant 11 and 23 months, 7 patients
died of transplant related mortality (6 with infection and only one
with aGVHD) and another 55 (85.9%) got disease free survive.
There was significant difference of overall survival (OS) for patients
older or younger than 10 years(96% vs 71%, p5 0.037)and patients
with BMT than PBSCT or CBT(100% vs 85% and 67%, p5 0.05).
Although II-IV aGVHD was significant different between MSD,
MUD or haploidentical transplant (22.2%, 45% vs 66.6%, P 5
0.003)there was no any different of the OS among these three
groups(93%,85% vs 80%, P 5 0.526).
Conclusion: HSCT is an effective method to rescue children with
AA. Comparing with PB and CB, BM is much better for children
with AA. Although aGVHDwasmuch frequent inMUDand heploi-
dentical donor transplant, it can be controlled and without interfer-
ence with the OS. Because the outcome of MUD or haploidentical
donor transplantation is the same as MSD donor transplant, which
is much better than IST for pediatric AA in China. It is reasonable
to consider the high resolution well matched unrelated donor trans-
plant as the first line treatment for SAA children in our country.453
IMPACT OF DONOR TYPE IN ALLOGENEIC TRANSPLANTATION (allo SCT)
FOR PEDIATRIC MALIGNANCIES
Barriga, F.1, Wietstruck, A.1, Rojas, N.1, Zu~niga, P.1, Borghero, Y.
1CAtholic University of Chile, Santiago, Santiago, Chile
Allo SCT is the treatment of choice for various pediatric malig-
nancies. A matched sibling donor (MSD) is always preferable but
only 25%of pts have such a donor. All other pts have to receive trans-
plants from unrelated donors (URD), either adult volunteers or cord
blood units. Transplant results with URD for children with hemato-
logic malignancies have improved due to the increase in the donor
pool and more experience of transplant centers (BMT
2004;34:901, Blood 2010; 116: 1839). We review our experience
with allo SCT for children with hematological malignancies com-
paring the results between MSD vs URD grafts.
Patients and Methods: 61 pediatric pts. received an allo SCT for
hematologic malignancy from 1989 through 2010 at a single institu-
tion. 40 received the graft from MSD and 21 from URD (18 pts 0-1
mismatch cord blood unit and 3 full matched adult donors). Both
groups were balanced for diagnosis (ALL 52% vs 52%, AML 32%
vs 33%, CML/MDS 15% vs 14%), disease stage (ALL and AML:
CR1 35% vs 33%, CR2 35% vs 38%, . CR2/refractory 14% vs
10%) and use of TBI in the conditioning regimen (78% vs 90%).
Overall survival, relapse and transplant related mortality (TRM,
any time after SCT) were analysed with the Kaplan Meier method
and compared with the LogRank test.
Results: with a median follow up time of 3 years overall survival is
46%; 45% for the MSD group and 48% for the URD. Relapse
was 50% for MSD vs 29% for URD (p 5 0,09) and MRT was
21% for MSD vs 32% for URD (p 5 0,33).
Conclusion: pediatric pts. with hematologic malignancies and a def-
inite indication for allo SCT should proceed to transplant as soon as
an adequate donor is found (MSD or URD).
